IMMUNOMODULATORY AGENTS AND PROTEASOME INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA

被引：9

作者：

Noonan, Kimberly ^{[1
]}

Colson, Kathleen ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

SEMINARS IN ONCOLOGY NURSING | 2017年 / 33卷 / 03期

关键词：

multiple myeloma; immunomodulatory drugs; proteasome inhibitors; treatment; side effects; LENALIDOMIDE PLUS DEXAMETHASONE; STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE; NEWLY-DIAGNOSED MYELOMA; LONG-TERM SURVIVAL; ELDERLY-PATIENTS; OPEN-LABEL; CONSENSUS STATEMENT; ANTITUMOR-ACTIVITY; ORAL MELPHALAN;

D O I：

10.1016/j.soncn.2017.05.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OBJECTIVE: To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). DATA SOURCES: Journal articles, research reports, state of the science papers, and clinical guidelines. CONCLUSION: There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens. IMPLICATIONS FOR NURSING PRACTICE: With these advances in the therapeutic landscape, knowledge of these drugs, side effects and nursing implications are essential to improve outcomes. Patient education is also of vital importance in achieving optimal responses to treatment.

引用

下载

页码：279 / 291

页数：13

共 50 条

[41] Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
T Hideshima
F Cottini
H Ohguchi
J Jakubikova
G Gorgun
N Mimura
Y-T Tai
N C Munshi
P G Richardson
K C Anderson
Blood Cancer Journal, 2015, 5 : e312 - e312
[42] Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
Hideshima, T.
Cottini, F.
Ohguchi, H.
Jakubikova, J.
Gorgun, G.
Mimura, N.
Tai, Y-T
Munshi, N. C.
Richardson, P. G.
Anderson, K. C.
BLOOD CANCER JOURNAL, 2015, 5 : e312 - e312
[43] Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma
Zhang, Wen
Wang, Xueyuan
Zhang, Haoyang
Wen, Tiantian
Yang, Lin
Miao, Hang
Wang, Jia
Liu, Hailong
Yang, Xu
Lei, Meng
Zhu, Yongqiang
BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 40
[44] Proteasome inhibitor for treatment of multiple myeloma
Ahmad, K
LANCET ONCOLOGY, 2005, 6 (08): : 546 - 546
[45] Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
Oostvogels, Rimke
Jak, Margot
Raymakers, Reinier
Mous, Rogier
Minnema, Monique C.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 60 - 67
[46] Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma
Cole, Daniel C.
Frishman, William H.
CARDIOLOGY IN REVIEW, 2018, 26 (03) : 122 - 129
[47] Proteasome inhibitors in multiple myeloma: 10 years later
Moreau, Philippe
Richardson, Paul G.
Cavo, Michele
Orlowski, Robert Z.
San Miguel, Jesus F.
Palumbo, Antonio
Harousseau, Jean-Luc
BLOOD, 2012, 120 (05) : 947 - 959
[48] Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
Leleu, Xavier
Martin, Thomas G.
Einsele, Hermann
Lyons, Roger M.
Durie, Brian G. M.
Iskander, Karim S.
Ailawadhi, Sikander
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01): : 9 - 22
[49] Nonselective proteasome inhibitors in multiple myeloma and future perspectives
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Ntanasis-Stathopoulos, Ioannis
Dimopoulos, Meletios Athanasios
EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (03) : 335 - 347
[50] New orally active proteasome inhibitors in multiple myeloma
Allegra, Alessandro
Alonci, Andrea
Gerace, Demetrio
Russo, Sabina
Innao, Vanessa
Calabro, Laura
Musolino, Caterina
LEUKEMIA RESEARCH, 2014, 38 (01) : 1 - 9

← 1 2 3 4 5 →